



Final Appraisal Recommendation

Advice No: 0418 – February 2018

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) 800 mg/150 mg/200 mg/10 mg film-coated tablet

Limited submission by Janssen-Cilag Ltd

Recommendation of AWMSG

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2418), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Janssen-Cilag Ltd
Date of first issue	February 2018
Last reviewed	March 2021

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0418:
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) 800 mg/150 mg/200 mg/10 mg film-coated tablet. February 2018.